|
European Acute Otitis Media Study
Cefprozil vs -lactamase inhibitor-containing control drug EFFICACY:
Pathogen % of Cases with Pathogen Outcome (n= 47) S. pneumoniae 51.0% cefprozil equivalent to control H. influenzae 29.8% cefprozil equivalent to control M. catarrhalis 6.4% cefprozil equivalent to control S. pyogenes 12.8% cefprozil equivalent to control Overall 100.0% cefprozil equivalent to control SAFETY: The incidence of adverse events in the cefprozil arm was comparable to the incidence of adverse events in the control arm (agent that contained a specific -lactamase inhibitor). Text Continues Below
REFERENCES 1. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically ÑThird Edition. Approved Standard NCCLS Document M7-A3, Vol. 13, No. 25, NCCLS, Villanova, PA, December 1993. 2. National Committee for Clinical Laboratory Standards. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria ÑThird Edition. Approved Standard NCCLS Document M11-A3, Vol. 13, No. 26, NCCLS, Villanova, PA, December 1993. 3. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests ÑFifth Edition. Approved Standard NCCLS Document M2-A5, Vol. 13, No. 24, NCCLS, Villanova, PA, December 1993. E2-B0001-12-03 7718DIM-14 Revised December 2003
Bottle Final Concentration Final Concentration Size 125 mg/ 5 mL 250 mg/ 5 mL
50 mL 36 mL 36 mL
75 mL 54 mL 54 mL
100 mL 72 mL 72 mL Page: << Prev | 1 | 2 | 3 | 4 | 5
|
.gif)
